Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation
摘要:
A series of novel 1-benzhydryl-sulfonyl-piperazine derivatives 7(a-e) were designed by a nucleophilic substitution reaction of 1-benzhydryl-piperazine with various sulfonyl chlorides and characterized by H-1 nuclear magnetic resonance (NMR), liquid chromatography mass spectrometry (LC/MS), Fourier-transform infrared (FTIR), and elemental analysis. Our research is focused on identifying synthetically occurring chemotherapeutic substances capable of inhibiting, retarding, or reversing the process of multistage carcinogenesis. The title compounds were evaluated for their efficacy in inhibiting MDA-MB-231 breast cancer cell proliferation. Compound 1-benzhydryl-4-(4-tert-butyl-benzenesulfonyl)-piperazine (7d) showed significant inhibitory activity.
N-cyclic sulfonamido inhibitors of gamma secretase
申请人:Neitzel L. Martin
公开号:US20060035884A1
公开(公告)日:2006-02-16
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer's Disease.
Compounds of particular interest are defined by Formula I, wherein R
4
, R
5
, R
6
, R
7
, and R
8
, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula I.
本发明提供了用于治疗或预防认知障碍(如阿尔茨海默病)的 N-环磺酰胺基化合物。
特别感兴趣的化合物由式 I 定义,其中 R
4
, R
5
, R
6
, R
7
和 R
8
如说明书所述。本发明还包括由式 I 化合物组成的药物组合物,以及使用式 I 化合物治疗认知障碍(包括阿尔茨海默病)的方法。
N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE
申请人:ELAN PHARMACEUTICALS, INC.
公开号:EP1758884A2
公开(公告)日:2007-03-07
[EN] N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE<br/>[FR] INHIBITEURS SULFONAMIDO N-CYCLIQUES DE GAMMA-SECRETASE
申请人:ELAN PHARM INC
公开号:WO2005113542A2
公开(公告)日:2005-12-01
The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, R7 and R8 are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer’s disease using compounds of Formula (I).
Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation
作者:C. S. Ananda Kumar、S. Nanjunda Swamy、N. R. Thimmegowda、S. B. Benaka Prasad、George W. Yip、K. S. Rangappa
DOI:10.1007/s00044-007-9022-y
日期:2007.9
A series of novel 1-benzhydryl-sulfonyl-piperazine derivatives 7(a-e) were designed by a nucleophilic substitution reaction of 1-benzhydryl-piperazine with various sulfonyl chlorides and characterized by H-1 nuclear magnetic resonance (NMR), liquid chromatography mass spectrometry (LC/MS), Fourier-transform infrared (FTIR), and elemental analysis. Our research is focused on identifying synthetically occurring chemotherapeutic substances capable of inhibiting, retarding, or reversing the process of multistage carcinogenesis. The title compounds were evaluated for their efficacy in inhibiting MDA-MB-231 breast cancer cell proliferation. Compound 1-benzhydryl-4-(4-tert-butyl-benzenesulfonyl)-piperazine (7d) showed significant inhibitory activity.